TP53 and neoplasm: Specifically, in p53‐deficient tumours, USP14 activity may lead to increased stability of cell cycle proteins such as cyclin E1, promoting tumour cell proliferation and inhibiting the degradation of apoptosis‐related proteins, enhancing tumour cell survival.